AAVivo to Present Groundbreaking In Vivo CAR-T Data at ASGCT 2026 Annual Meeting in Boston

Sponsored Symposium to Highlight CD3scFv-Engineered AAV Capsids Achieving Superior CAR-T Cell Generation and Complete Tumor Eradication in Preclinical Models

Boston, MA – March 31, 2026 – AAVivo, a Delaware-registered biotechnology company focused on next-generation AAV-based gene therapies and supported by Virovek, today announced that it will host a sponsored symposium at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, taking place May 11–15, 2026, in Boston, Massachusetts.

The symposium, titled “Breaking Barriers in In Vivo CAR-T Therapy: CD3scFv-Engineered AAV Capsids Drive Superior CAR-T Cell Generation and Complete Tumor Eradication,” will showcase compelling new preclinical data from AAVivo’s proprietary AAVTCeT platform.

During the session, the company will present evidence demonstrating how its CD3scFv-engineered AAV capsids enable highly efficient in vivo CAR-T cell generation, resulting in complete tumor eradication in preclinical models. This innovative approach addresses major limitations of traditional ex vivo CAR-T therapies, including complex and costly manufacturing processes, limited patient accessibility, and scalability challenges.

“Presenting at ASGCT 2026 provides an important platform to share our progress toward transforming CAR-T therapy,” said Haifeng Chen, PhD, CEO of AAVivo. “Our AAVTCeT platform has the potential to deliver an off-the-shelf, in vivo solution that could significantly improve patient outcomes and broaden access to life-changing cell therapies. We look forward to engaging with the gene and cell therapy community and potential partners in Boston.”

Symposium Details

• Title: Breaking Barriers in In Vivo CAR-T Therapy: CD3scFv-Engineered AAV Capsids Drive Superior CAR-T Cell Generation and Complete Tumor Eradication
• Date & Time: Friday, May 15, 2026 | 10:15 – 10:45 AM
• Location: Room 109AB, Thomas M. Menino Convention & Exhibition Center, Boston, MA
• Format: Sponsored Symposium (open to ASGCT 2026 registered attendees; also livestreamed via the ASGCT Events App)

The presentation will include an overview of the AAVTCeT platform technology, key preclinical efficacy and safety data, and the company’s development roadmap for clinical translation.

AAVivo is advancing its platform with the support of Virovek’s established AAV expertise to develop more accessible and cost-effective genetic medicines.

For more information about AAVivo or to schedule a meeting during the ASGCT 2026 Annual Meeting, please contact:
Haifeng Chen, PhD
CEO, AAVivo
Email: hchen@virovek.com
Phone: 510-280-4909
Website: www.aavivo.com

About AAVivo
AAVivo is a Delaware-registered biotechnology company developing next-generation AAV-based platforms for in vivo cell and gene therapies. Supported by Virovek, AAVivo aims to overcome key barriers in CAR-T and other genetic medicines by enabling efficient, scalable, and accessible treatment options. For more information, visit www.aavivo.com.